FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415156871> ?p ?o ?g. }

• W2415156871 abstract "Abstract Prognosis of acute myeloid leukemia (AML) is mainly determined by presenting cyto- and molecular genetics, as systematized in the recent European LeukemiaNet (ELN) risk classification. Moreover, mutational profiling is currently used to assign post-remission therapy, especially in the category of intermediate-risk cytogenetics (IR-AML), given the observed benefit of allogeneic hematopoietic stem-cell transplantation (alloHSCT) in first complete response in patients harboring high-risk molecular features such as FLT3-ITD and the lack of benefit in patients with a favorable genotype (i.e., mutated NPM1 and CEBPA biallelic mutation). Nonetheless, the prognosis for patients with an IR-AML lacking mutations of these three genes (“triple negative” AML) is uncertain, and optimal post-remission strategy for these bona fide intermediate-risk patients is mostly unknown. In order to elucidate if alloHSCT could improve the prognosis of this molecular subgroup, we analyzed the outcome in a large series of patients with “de novo”, IR-AML (70% harboring a normal karyotype), diagnosed between 2000 and 2013, lacking mutations of NPM1, FLT3-ITD, and CEBPA (only patients with biallelic mutations were excluded), who had achieved a first complete remission after 1 or 2 courses of standard induction therapy. These 630 patients (median age, 52 years, range, 18-72; 58% male) have been included in the database of three different cohorts, the cooperative AML groups AMLSG (n=239) and Spanish CETLAM (n=146), and the HSCT registry of the ALWP-EBMT (n=245). The prognostic impact of alloHSCT in CR1 was analyzed as a time-dependent variable in univariable (Mantel-Byar method, Simon-Makuch plots) and multivariable (Cox with time dependent-variable) analyses. After a median follow-up of 37 months, 3-year survival (OS), leukemia free-survival (LFS) and relapse incidence (RI) in the pooled two subgroups of AMLSG and CETLAM cooperative groups, regardless of post-remission therapy, was 53% [95% CI: 47-58], 36% [95% CI: 31-41], and 51% [95% CI=45-56], respectively (57±3%, 37.5±3%, and 44±4% in patients up to 60 year-old, respectively), without significant differences between both cohorts. In order to investigate the potential benefit of alloHSCT, we analyzed the entire group, including also patients from the ALWP-EBMT cohort. Remarkably, the outcome of patients from national cooperative groups AMLSG-CETLAM compared to registry ALWP-EBMT who received an alloHSCT in CR1 was not statistically different (3-year OS, LFS, and RI: 57 vs. 68%, p=0.13; 61 vs. 73%, p=0.08; and 22 vs. 19%, p=0.67). Patients who received an alloHSCT in CR1 (n=396) had an improved outcome compared to other post-remission options (high-dose cytarabine based chemotherapy, n=189; autoHSCT, n=45) with a higher OS (3-yr: 65 vs. 49%, p=7x10-5) and LFS (3-yr: 60 vs. 26%, p<10-13), and lower RI (3-yr: 23 vs. 72%, p<10-16). Moreover, post-remission option (alloHSCT in CR1 vs. other), as time-dependent variable, was the strongest prognostic factor in the multivariate analysis in terms of OS (HR=0.61, 0.46-0.8; p=0.0003), LFS (HR=0.49, 0.37-0.65; p<0.0001), and RI (HR=0.24, 0.17-0.34, p<0.001). Other independent prognostic factors identified were age for OS (HR=1.24, 1.11-1.40 -by 10 years-; p=0.0004) and LFS (HR: 1.21, 1.08-1.34; p=0.0007), presenting WBC at diagnosis for OS (HR=1.29, 1-1.67 –over median-; p=0.05), and female gender for OS (HR=0.74, 0.57-0.97; p=0.03). Interestingly, the outcome after alloHSCT did not differ depending on donor type (2-yr RI, LFS, and OS: 14 vs. 19%, p=0.97; 67 vs. 68%, p=0.42; 73 vs. 72%, p=0.95 after alloHSCT with matched sibling, n=200, or an unrelated donor, n=183, respectively). In conclusion, IR-AML patients with a triple negative genotype constitute a subgroup with a high risk of relapse after postremission therapy with high-dose cytarabine based chemotherapy or autoHSCT. This large study, involving patients from two cooperative groups and the EBMT registry, indicates that an alloHSCT in first CR is associated with a marked relapse reduction and survival benefit in the two cooperative group cohorts with prospective treatment data as well as in the whole cohort including the EBMT registry data. Disclosures No relevant conflicts of interest to declare." @default.
• W2415156871 created "2016-06-24" @default.
• W2415156871 creator A5003572390 @default.
• W2415156871 creator A5006173909 @default.
• W2415156871 creator A5008084507 @default.
• W2415156871 creator A5010010012 @default.
• W2415156871 creator A5013231760 @default.
• W2415156871 creator A5014705544 @default.
• W2415156871 creator A5017225753 @default.
• W2415156871 creator A5022161221 @default.
• W2415156871 creator A5023855466 @default.
• W2415156871 creator A5025996929 @default.
• W2415156871 creator A5040417184 @default.
• W2415156871 creator A5043541529 @default.
• W2415156871 creator A5053578678 @default.
• W2415156871 creator A5053949970 @default.
• W2415156871 creator A5053983155 @default.
• W2415156871 creator A5058195823 @default.
• W2415156871 creator A5058925624 @default.
• W2415156871 creator A5066560929 @default.
• W2415156871 creator A5073550101 @default.
• W2415156871 creator A5075459915 @default.
• W2415156871 creator A5075950572 @default.
• W2415156871 creator A5081614049 @default.
• W2415156871 creator A5081804029 @default.
• W2415156871 creator A5084354003 @default.
• W2415156871 creator A5085817630 @default.
• W2415156871 creator A5086668079 @default.
• W2415156871 creator A5089395073 @default.
• W2415156871 date "2014-12-06" @default.
• W2415156871 modified "2023-10-17" @default.
• W2415156871 title "Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT" @default.
• W2415156871 doi "https://doi.org/10.1182/blood.v124.21.324.324" @default.
• W2415156871 hasPublicationYear "2014" @default.
• W2415156871 type Work @default.
• W2415156871 sameAs 2415156871 @default.
• W2415156871 citedByCount "0" @default.
• W2415156871 crossrefType "journal-article" @default.
• W2415156871 hasAuthorship W2415156871A5003572390 @default.
• W2415156871 hasAuthorship W2415156871A5006173909 @default.
• W2415156871 hasAuthorship W2415156871A5008084507 @default.
• W2415156871 hasAuthorship W2415156871A5010010012 @default.
• W2415156871 hasAuthorship W2415156871A5013231760 @default.
• W2415156871 hasAuthorship W2415156871A5014705544 @default.
• W2415156871 hasAuthorship W2415156871A5017225753 @default.
• W2415156871 hasAuthorship W2415156871A5022161221 @default.
• W2415156871 hasAuthorship W2415156871A5023855466 @default.
• W2415156871 hasAuthorship W2415156871A5025996929 @default.
• W2415156871 hasAuthorship W2415156871A5040417184 @default.
• W2415156871 hasAuthorship W2415156871A5043541529 @default.
• W2415156871 hasAuthorship W2415156871A5053578678 @default.
• W2415156871 hasAuthorship W2415156871A5053949970 @default.
• W2415156871 hasAuthorship W2415156871A5053983155 @default.
• W2415156871 hasAuthorship W2415156871A5058195823 @default.
• W2415156871 hasAuthorship W2415156871A5058925624 @default.
• W2415156871 hasAuthorship W2415156871A5066560929 @default.
• W2415156871 hasAuthorship W2415156871A5073550101 @default.
• W2415156871 hasAuthorship W2415156871A5075459915 @default.
• W2415156871 hasAuthorship W2415156871A5075950572 @default.
• W2415156871 hasAuthorship W2415156871A5081614049 @default.
• W2415156871 hasAuthorship W2415156871A5081804029 @default.
• W2415156871 hasAuthorship W2415156871A5084354003 @default.
• W2415156871 hasAuthorship W2415156871A5085817630 @default.
• W2415156871 hasAuthorship W2415156871A5086668079 @default.
• W2415156871 hasAuthorship W2415156871A5089395073 @default.
• W2415156871 hasConcept C104317684 @default.
• W2415156871 hasConcept C126322002 @default.
• W2415156871 hasConcept C143998085 @default.
• W2415156871 hasConcept C174475383 @default.
• W2415156871 hasConcept C2483381 @default.
• W2415156871 hasConcept C2776694085 @default.
• W2415156871 hasConcept C2777408962 @default.
• W2415156871 hasConcept C2778461978 @default.
• W2415156871 hasConcept C2778729363 @default.
• W2415156871 hasConcept C2911091166 @default.
• W2415156871 hasConcept C30481170 @default.
• W2415156871 hasConcept C45091340 @default.
• W2415156871 hasConcept C501734568 @default.
• W2415156871 hasConcept C53226629 @default.
• W2415156871 hasConcept C54355233 @default.
• W2415156871 hasConcept C71924100 @default.
• W2415156871 hasConcept C86803240 @default.
• W2415156871 hasConceptScore W2415156871C104317684 @default.
• W2415156871 hasConceptScore W2415156871C126322002 @default.
• W2415156871 hasConceptScore W2415156871C143998085 @default.
• W2415156871 hasConceptScore W2415156871C174475383 @default.
• W2415156871 hasConceptScore W2415156871C2483381 @default.
• W2415156871 hasConceptScore W2415156871C2776694085 @default.
• W2415156871 hasConceptScore W2415156871C2777408962 @default.
• W2415156871 hasConceptScore W2415156871C2778461978 @default.
• W2415156871 hasConceptScore W2415156871C2778729363 @default.
• W2415156871 hasConceptScore W2415156871C2911091166 @default.
• W2415156871 hasConceptScore W2415156871C30481170 @default.
• W2415156871 hasConceptScore W2415156871C45091340 @default.
• W2415156871 hasConceptScore W2415156871C501734568 @default.
• W2415156871 hasConceptScore W2415156871C53226629 @default.
• W2415156871 hasConceptScore W2415156871C54355233 @default.
• W2415156871 hasConceptScore W2415156871C71924100 @default.
• W2415156871 hasConceptScore W2415156871C86803240 @default.
• W2415156871 hasLocation W24151568711 @default.

• next